Nektar Therapeutics to Present at the UBS 2009 Global Life Sciences Conference in New York City
Posted on: Friday, 18 September 2009, 14:07 CDT
SAN CARLOS, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) is scheduled to present at the upcoming UBS 2009 Global Life Sciences Conference in New York at the Grand Hyatt Hotel on Tuesday, September 22, 2009 at 10:30 a.m. Eastern time.
The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until October 25, 2009.
About Nektar
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for partners, which include leading biopharmaceutical companies, including UCB's Cimzia(R), Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia. Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, PEGylated docetaxel, is currently in a Phase 1 clinical study in patients with refractory solid tumors.
Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Nektar Contacts: Jennifer Ruddock Nektar Therapeutics 650-631-4954 jruddock@nektar.com Susan Noonan The SAN Group 212-966-3650 susan@sanoonan.comSOURCE Nektar Therapeutics
Source: PR Newswire
Related Articles
- Nektar Therapeutics Reports Third Quarter 2009 Financial Results
- Nektar Therapeutics to Host Conference Call to Discuss Today's Announcement of a New Partnership for NKTR-118 and NKTR-119
- Nektar Therapeutics Reports Second Quarter 2009 Financial Results
- Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
- Nektar Therapeutics Reports First Quarter 2009 Financial Results
- Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
- Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
- Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-Irinotecan)
- Nektar Presents Positive Results From Phase 1 Clinical Trial of NKTR-118 (Oral PEG-Naloxol) at American College of Clinical Pharmacology Meeting
 |
 |
User Comments (0)
RSS Feeds